Annually since January 2013, the Clarivate™ expert team has analyzed and selected the Drugs to Watch™. While the underlying process has remained the same, the technologies have evolved and new tools, such as Drug Timelines & Success Rates, are now available to inform the analysis.
| Drug Name | Company | Therapy Area | Year |
| Donanemab | Eli Lilly and Co. | Alzheimer’s disease | 2022, 2023 |
| Lecanemab | Biogen Inc., Esai Co Ltd. | Alzheimer’s disease | 2022, 2023 |
| Bimekizumab | UCB | Plaque psoriasis | 2021, 2023 |
| Faricimab | Roche and Chugai Pharmaceutical | Diabetic macular edema and wet age-related macular degeneration | 2022 |
| Adagrasib | Mirati Therapeutics, Zai Lab Limited | KRASG12C-positive NSCLC and CRC | 2022 |
| Vutrisiran | Alnylam Pharmaceuticals Inc. | Transthyretin-mediated amyloidosis-related polyneuropathy | 2022 |
| Tirzepatide | Eli Lilly and Co. | Type 2 diabetes mellitus | 2022 |
| Tezepelumab | Amgen, AstraZeneca plc | Severe asthma | 2022 |
| Aducanumab | Biogen Inc., Esai Co Ltd. | Alzheimer’s disease, Neurology/psychiatric | 2021 |
| Relugolix | ASKA Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. | Oncology - prostate cancer, Reproductive health - endometriosis & uterine fibroids | 2021 |
| Vericiguat | Bayer AG, Merck & Co. | Cardiovascular – heart failure | 2021 |
| Filgotinib (GLPG-0634) | Galapagos NV, Gilead Sciences Inc. | Excessive immune response/autoimmunity | 2020 |
| Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) | The Medicines Co. | Cardiovascular disease | 2020 |
| Lisocabtagene maraleucel (JCAR-017; Liso-cel) | Celgene Corporation | Oncology | 2020 |
| Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | Neurology/psychiatric | 2020 |
| Ozanimod (RPC-1063; Zeposia) | Celgene Corporation | Neurology/psychiatric | 2020 |
| Rimegepant (BHV-3000; Nurtec) | Biohaven Pharmaceutical Holding Co. Ltd. | Neurology/psychiatric | 2020 |
| Sacituzumab govitecan (IMMU-132) | Immunomedics Inc., Medicine Inc. | Oncology | 2020 |
| Semaglutide (Rybelsus) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2020 |
| Trastuzumab deruxtecan (DS-8201a; Enhertu) | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Oncology | 2020 |
| Vadadustat | Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | Chronic disease complication | 2020 |
| Valoctocogene roxaparvovec (BMN-270; Valrox) | Biomarin Pharmaceutical Inc. | Genetic disorder | 2020 |
| Betibeglogene darolentivec (LentiGlobin) | Bluebird Bio Inc. | Genetic disorder | 2019 |
| Onasemnogene abeparvovec (AVXS-101; Zolgensma) | AveXis | Genetic disorder | 2019 |
| Palforzia (AR101; Aerumab) | Aimmune Therapeutics | Excessive immune response/autoimmunity | 2019 |
Among the major factors shaping the global pharmaceutical market in 2023 are increasing demand for biologics from Mainland China, the rise of biosimilars, progress toward personalized medicines and the urgency of addressing the diseases highlighted in the United Nations Sustainable Development Goals.
Access global intelligence, advanced analytics and global experts from Clarivate.